Mindera Health, developer of Mind.Px, is partnering with pharmacy benefit manager Liviniti to improve the management of moderate-to-severe psoriasis via precision medicine.
Using a patented dermal biomarker patch, Mind.Px prospectively predicts a patient’s response to biologic drug classes prior to therapeutic selection and treatment. The patch captures more than 7,000 biomarkers per sample through a rapid and painless extraction of mRNA from skin. This is followed by transcriptomic analysis and machine learning-derived classifiers that provide actionable results for clinicians with >92% positive predictive value, improving patient outcomes and significantly reducing healthcare costs of expensive biologic treatments.
Specialty drug spending for psoriasis is escalating exponentially and biologics are often identified by payers, employers, and pharmacy benefit managers as being in their top drug expenditures each year. Furthermore, successful patient responses to currently available biologic treatments are roughly 52%, leading to trial-and-error patient treatments and increased healthcare costs. Mind.Px can improve clinical outcomes while reducing biologic drug costs for self-funded employers, the Company states.
“We are delighted to partner with a Pharmacy Benefit Manager like Liviniti to introduce precision medicine to psoriasis patients,” says Ron Rocca, CEO of Mindera Health, in a news release. “We share the core value of introducing innovation to significant markets to decrease drug costs while improving patient outcomes.”
LeAnn C. Boyd, Liviniti CEO adds, “Inflammatory conditions are a major cost trend driver in the specialty pharmacy space. Leveraging pharmacogenomics through our collaboration with Mindera Health supports improved treatment outcomes for patients with psoriasis and reduced plan costs for expensive biologics. Ensuring that patients receive an effective drug early in treatment is a cornerstone of this program, and we are excited to offer Mind.Px to our clients and their members.”
